Journal of Neurology

, Volume 259, Issue 11, pp 2491–2493 | Cite as

4-Aminopyridine and cerebellar gait: a retrospective case series

  • Roman Schniepp
  • Max Wuehr
  • Maximilian Neuhaeusser
  • Ann Kathrin Benecke
  • Christine Adrion
  • Thomas Brandt
  • Michael Strupp
  • Klaus Jahn
Letter to the Editors

Notes

Acknowledgments

The authors thank Judy Benson for copy-editing the manuscript. The work was supported by the German research foundation (Deutsche Forschungsgemeinschaft, DFG JA 1087/1-1), the German Hertie Foundation and the Federal Ministry for Education and Science (BMBF 01EO0901) of Germany.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Supplementary material

415_2012_6595_MOESM1_ESM.eps (850 kb)
Supplementary material 1 (EPS 849 kb)
415_2012_6595_MOESM2_ESM.eps (864 kb)
Supplementary material 2 (EPS 863 kb)
415_2012_6595_MOESM3_ESM.doc (58 kb)
Supplementary material 3 (DOC 58 kb)

References

  1. 1.
    Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268PubMedCrossRefGoogle Scholar
  2. 2.
    Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502PubMedCrossRefGoogle Scholar
  3. 3.
    Hausdorff JM (2005) Gait variability: methods, modeling and meaning. J Neuroeng Rehabil 2:19PubMedCrossRefGoogle Scholar
  4. 4.
    Ilg W, Brotz D, Burkard S, Giese MA, Schols L, Synofzik M (2010) Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord 25:2239–2246PubMedCrossRefGoogle Scholar
  5. 5.
    Ilg W, Golla H, Thier P, Giese MA (2007) Specific influences of cerebellar dysfunctions on gait. Brain 130:786–798PubMedCrossRefGoogle Scholar
  6. 6.
    Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L (2009) Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73:1823–1830PubMedCrossRefGoogle Scholar
  7. 7.
    Kalla R, Glasauer S, Buttner U, Brand T, Strupp M (2007) 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 130:2441–2451PubMedCrossRefGoogle Scholar
  8. 8.
    Schniepp R, Wuehr M, Ackl N, Danek A, Brandt T, Strupp M, Jahn K (2011) 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol 258:1708–1711PubMedCrossRefGoogle Scholar
  9. 9.
    Schniepp R, Wuehr M, Neuhaeusser M, Kamenova M, Dimitriadis K, Klopstock T, Strupp M, Brandt T, Jahn K (2012) Locomotion speed determines gait variability in cerebellar ataxia and vestibular failure. Mov Disord 27(1):125–131PubMedCrossRefGoogle Scholar
  10. 10.
    Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62:1623–1625PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Roman Schniepp
    • 1
    • 2
  • Max Wuehr
    • 2
  • Maximilian Neuhaeusser
    • 3
  • Ann Kathrin Benecke
    • 1
  • Christine Adrion
    • 5
  • Thomas Brandt
    • 2
    • 4
  • Michael Strupp
    • 1
    • 2
  • Klaus Jahn
    • 1
    • 2
  1. 1.Department of Neurology, Campus GrosshadernUniversity of MunichMunichGermany
  2. 2.Integrated Research and Treatment Center for Vertigo, Balance and Ocular Motor Disorders: IFB(LMU)University of MunichMunichGermany
  3. 3.Graduate School of Systemic NeurosciencesUniversity of MunichMunichGermany
  4. 4.Institute of Clinical NeurosciencesUniversity of MunichMunichGermany
  5. 5.Institute for Medical Information Sciences, Biometry and Epidemiology (IBE)University of MunichMunichGermany

Personalised recommendations